MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

2.94 -3.29

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.93

Максимум

2.9699999999999998

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+577.97% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-114M 274M
Предишно отваряне	6.23
Предишно затваряне	2.94

Настроения в новините

By Acuity

20%

80%

37 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12.04.2026 г., 23:38 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12.04.2026 г., 23:38 ч. UTC

Пазарно говорене

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12.04.2026 г., 23:31 ч. UTC

Пазарно говорене

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12.04.2026 г., 23:09 ч. UTC

Пазарно говорене

Значими събития в новините

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12.04.2026 г., 23:06 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

12.04.2026 г., 23:06 ч. UTC

Пазарно говорене

Australian Dollar Ripe for a Downward Correction -- Market Talk

12.04.2026 г., 22:56 ч. UTC

Значими събития в новините

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12.04.2026 г., 22:54 ч. UTC

Значими събития в новините

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12.04.2026 г., 22:53 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12.04.2026 г., 22:51 ч. UTC

Значими събития в новините

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12.04.2026 г., 22:50 ч. UTC

Пазарно говорене

Значими събития в новините

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12.04.2026 г., 22:37 ч. UTC

Пазарно говорене

Значими събития в новините

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

11.04.2026 г., 00:00 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Big Yachts, Big Bucks -- Barrons.com

10.04.2026 г., 21:55 ч. UTC

Придобивния, сливания и поглъщания

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10.04.2026 г., 21:01 ч. UTC

Печалби

Cango Inc.: Files Annual Report on Form 20-F With SEC

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.04.2026 г., 20:31 ч. UTC

Пазарно говорене

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10.04.2026 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Lower -- Market Talk

10.04.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

577.97% нагоре

12-месечна прогноза

Среден 20 USD 577.97%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

37 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.